Larder BA - Search Results

1

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.

Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Nájera I, Kohli A, Larder BA. Harrigan PR, et al. Among authors: larder ba. J Virol. 1996 Sep;70(9):5930-4. doi: 10.1128/JVI.70.9.5930-5934.1996. J Virol. 1996. PMID: 8709214 Free PMC article.

2

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.

Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD. Harrigan PR, et al. J Virol. 2002 Jul;76(13):6836-40. doi: 10.1128/jvi.76.13.6836-6840.2002. J Virol. 2002. PMID: 12050397 Free PMC article.

3

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder B. Harrigan PR, et al. J Infect Dis. 2000 Mar;181(3):912-20. doi: 10.1086/315317. J Infect Dis. 2000. PMID: 10720512

4

Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Lacey SF, Reardon JE, Furfine ES, Kunkel TA, Bebenek K, Eckert KA, Kemp SD, Larder BA. Lacey SF, et al. Among authors: larder ba. J Biol Chem. 1992 Aug 5;267(22):15789-94. J Biol Chem. 1992. PMID: 1379238 Free article.

5

Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.

Larder BA, Coates KE, Kemp SD. Larder BA, et al. J Virol. 1991 Oct;65(10):5232-6. doi: 10.1128/JVI.65.10.5232-5236.1991. J Virol. 1991. PMID: 1716689 Free PMC article.

6

Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.

Larder BA, Kemp SD, Purifoy DJ. Larder BA, et al. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4803-7. doi: 10.1073/pnas.86.13.4803. Proc Natl Acad Sci U S A. 1989. PMID: 2472634 Free PMC article.

7

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Larder BA, Kemp SD. Larder BA, et al. Science. 1989 Dec 1;246(4934):1155-8. doi: 10.1126/science.2479983. Science. 1989. PMID: 2479983

8

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Larder BA, Kemp SD, Harrigan PR. Larder BA, et al. Science. 1995 Aug 4;269(5224):696-9. doi: 10.1126/science.7542804. Science. 1995. PMID: 7542804 Clinical Trial.

9

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Tisdale M, Kemp SD, Parry NR, Larder BA. Tisdale M, et al. Among authors: larder ba. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6. doi: 10.1073/pnas.90.12.5653. Proc Natl Acad Sci U S A. 1993. PMID: 7685907 Free PMC article.

10

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.

Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Larder BA, et al. J Virol. 1996 Sep;70(9):5922-9. doi: 10.1128/JVI.70.9.5922-5929.1996. J Virol. 1996. PMID: 8709213 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters